Optimization of enrichment conditions on TiO2 chromatography using glycerol as an additive reagent for effective phosphoproteomic analysis.

Metal oxide affinity chromatography (MOAC) represented by titanium dioxide (TiO2) chromatography has been used for phosphopeptide enrichment from cell lysate digests prior to mass spectrometry. For in-depth phosphoproteomic analysis, it is important for MOAC to achieve high phosphopeptide enrichment efficiency by optimizing purification conditions. However, there are some differences in phosphopeptide selectivity and specificity enriched by various TiO2 materials and procedures. Here, we report that binding/wash buffers containing polyhydric alcohols, such as glycerol, markedly improve phosphopeptide selectivity from complex peptide mixtures. In addition, the elution conditions combined with secondary amines, such as bis-Tris propane, made it possible to recover phosphopeptides with highly hydrophobic properties and/or longer peptide lengths. To assess the practical applicability of our improved method, we confirmed using PC3 prostate cancer cells. By combining the hydrophilic interaction chromatography (HILIC) with the optimized TiO2 enrichment method prior to LC-MS/MS analysis, over 8300 phosphorylation sites and 2600 phosphoproteins were identified. Additionally, some dephosphorylations of those were identified by treatment with dasatinib for a kinase inhibitor. These results indicate that our method is applicable to understanding the profiling of kinase inhibitors such as anticancer compounds, which will be useful for drug discovery and development.

Identification of potential prognostic markers for knee osteoarthritis by serum proteomic analysis.

BACKGROUND: As osteoarthritis (OA) is a highly heterogeneous disease in terms of progression, establishment of prognostic biomarkers would be highly beneficial for treatment. The present study was performed to identify novel biomarkers capable of predicting the progression of knee OA. METHODS: A total of 69 plasma samples (OA patients undergoing radiographic progression, n = 25; nonprogression, n = 33; healthy donors, n = 11) were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS), and ion peaks of interest were identified by liquid chromatography and matrix-assisted laser desorption/ionization (MALDI)-TOF MS. The identities of these proteins were further validated by immunoprecipitation combined with SELDI-TOF MS analysis. RESULTS: SELDI-TOF MS analysis indicated that the intensities of 3 ion peaks differed significantly between progressors and nonprogressors. Subsequent analyses indicated that these peaks corresponded to apolipoprotein C-I, C-III, and an N-terminal truncated form of transthyretin, respectively. The identities of these proteins were confirmed by the loss of ion peaks in SELDI-TOF MS spectra by immunoprecipitation using specific antibodies for the respective proteins. CONCLUSIONS: Three potential biomarkers were identified whose serum levels differed significantly between OA progressors and nonprogressors. These biomarkers are expected to be prognostic biomarkers for knee OA and to facilitate the development of novel disease-modifying treatments for OA.

Cyclic AMP-dependent Cl- secretion induced by thromboxane A2 in isolated human colon.

Increased release of thromboxane A(2) (TXA(2)) has been shown to be involved in inflammatory bowel diseases. In the present study, we have investigated the effect of a stable TXA(2) analogue (STA(2)) on the electrical parameters in isolated human colonic mucosa. In the human mucosa set between Ussing chambers, STA(2) stimulated Cl- secretion in a concentration-dependent manner with an EC(50) of 0.06 microm. The STA(2)-induced Cl- secretion was significantly inhibited by ONO-3708 (10 microm), a specific TXA(2) receptor antagonist. The effect of STA(2) (0.3 microm) was independent of the colonic segment from which the tissue was obtained, from caecum to rectum. Chromanol 293B, an inhibitor of the cAMP-dependent KvLQT1 channel, attenuated the STA(2)-induced Cl- secretion in the human colonic mucosa (IC(50) value 1.18 microm). We found that KvLQT1 mRNA and protein were expressed in all the tested segments of the human colon. The STA(2)-induced Cl- secretion was significantly inhibited by 8-bromo-2'-monobutyryladenosine-3',5'-cyclic monophosphorothioate (50 microm), a membrane-permeant cAMP antagonist. STA(2) (0.3 microm) significantly increased the intracellular cAMP levels and the short-circuit current via TXA(2) receptor in a human colonic cell line. These results suggest that the TXA(2)-induced Cl- secretion in the colon is mediated via the cAMP pathway in addition to the Ca(2+)-calmodulin pathway which was previously reported.

Leukotrienes-mediated effects of water extracts from Sargassum horneri, a marine brown alga, on Cl- absorption in isolated rat colon.

Sargassum horneri is an edible marine brown alga distributed along the seacoast of Japan. Here we examined effects on the water-soluble (ethanol-insoluble) extracts (EIS) from Sargassum horneri on ion transports across the isolated rat colonic mucosa set in Ussing chambers. The nonpolysaccharide fraction of EIS (EIS-2) significantly decreased short-circuit current (Isc) across the mucosa, and increased the tissue conductance (Gt). The half-maximal effect of EIS-2 was obtained at 20 microg/ml. In contrast, the polysaccharide fraction of EIS (EIS-1; 100 microg/ml) had little effect on Isc and Gt. The effect of EIS-2 depended on the presence of Cl- and HCO3- but not K+ in the bathing solution. These results suggest that EIS-2 stimulates Cl)absorption in the colonic mucosa. The EIS-2-induced changes in Isc and Gt were inhibited by 3-(1-[p-chlorobenzyl]-5-[isopropyl]-3-t-butylthioindol-2-yl)-2,2-dimethyl-propanoic acid sodium (MK-886; 10 microM), a 5-lipoxygenase-activating protein inhibitor, and 5-nitro-2-(3-phenylpropylamino)-benzoate (NPPB; 100 microM), a Cl- channel blocker. EIS-2 attenuated the prostaglandin E2 (0.5 microM)-increased Isc, and the half-maximal effect of EIS-2 was obtained at 50 microg/ml. The present study suggests that the EIS-2 stimulates Cl- absorption mediated by basolateral leukotriene-sensitive Cl- channels and apical Cl-/HCO3- exchanger in the rat colonic mucosa.

E3040 sulphate, a novel thromboxane synthase inhibitor, blocks the Cl- secretion induced by platelet-activating factor in isolated rat colon.

1. E3040 (6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole), is a novel dual inhibitor of 5-lipoxygenase (5-LOX) and thromboxane synthase (Tx synthase). Here, we examined the effects of E3040 sulphate, a sulphate conjugate of E3040, on these enzyme activities in cell-free systems and on the thromboxane A2 (TxA2)-mediated Cl- secretion induced by platelet-activating factor (PAF) in isolated rat colons. 2. E3040 sulphate inhibited Tx synthase activity in a concentration-dependent manner (IC50=0.013 microM), whereas it induced little effects on 5-LOX and cyclo-oxygenase activities (IC50>100 microM) with the cell-free enzyme assay. 3. With isolated rat colonic mucosa, E3040 sulphate in a concentration-dependent manner (IC50=1.8 microM) inhibited the Cl- secretion induced by 10 microM PAF. On the other hand, E3040 sulphate (30 microM) induced no effect on the prostaglandin E2 (0.5 microM)- and leukotriene D4 (1 microM)-induced Cl- secretion in the colon. 4. PAF (10 microM) increased a release of TxB2, a stable metabolite of TxA2, from the colonic mucosa. This increase was significantly inhibited by subsequent addition of E3040 sulphate (30 microM). 5. Probenecid (100 microM), an inhibitor of organic anion transporter, abolished the inhibitory effect of E3040 sulphate on the PAF-induced Cl- secretion. Another inhibitor, sulphobromophthalein (30 microM) partially but significantly attenuated the effect of E3040 sulphate. p-aminohippuric acid (1 mM) had no effect. 6. These findings suggest that E3040 sulphate is a novel Tx synthase inhibitor, and that E3040 sulphate taken up into the colonic cells by organic anion transporters inhibits the PAF-induced Cl- secretion by blocking a release of TxA2.